Greef Roderick De Sells 35,417 Shares of BioLife Solutions (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CEO Greef Roderick De sold 35,417 shares of BioLife Solutions stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $26.15, for a total value of $926,154.55. Following the completion of the transaction, the chief executive officer owned 454,581 shares of the company’s stock, valued at approximately $11,887,293.15. This represents a 7.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Greef Roderick De also recently made the following trade(s):

• On Thursday, November 13th, Greef Roderick De sold 31,165 shares of BioLife Solutions stock. The stock was sold at an average price of $25.33, for a total value of $789,409.45.
• On Wednesday, November 12th, Greef Roderick De sold 33,418 shares of BioLife Solutions stock. The shares were sold at an average price of $25.88, for a total value of $864,857.84.
• On Wednesday, October 22nd, Greef Roderick De sold 37,795 shares of BioLife Solutions stock. The shares were sold at an average price of $27.30, for a total value of $1,031,803.50.

BioLife Solutions Stock Performance

BioLife Solutions stock opened at $24.07 on Friday. The stock has a market capitalization of $1.16 billion, a P/E ratio of -200.57 and a beta of 1.97. The company’s fifty day moving average price is $26.55 and its 200 day moving average price is $24.12. BioLife Solutions, Inc. has a 1 year low of $19.10 and a 1 year high of $29.62.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of BLFS. Comerica Bank lifted its position in BioLife Solutions by 5.2% during the first quarter. Comerica Bank now owns 15,024 shares of the medical equipment provider’s stock worth $343,000 after buying an additional 746 shares in the last quarter. Principal Financial Group Inc. grew its holdings in BioLife Solutions by 6.2% in the 1st quarter. Principal Financial Group Inc. now owns 259,488 shares of the medical equipment provider’s stock valued at $5,927,000 after buying an additional 15,241 shares in the last quarter. Envestnet Asset Management Inc. increased its stake in shares of BioLife Solutions by 37.6% in the 1st quarter. Envestnet Asset Management Inc. now owns 273,329 shares of the medical equipment provider’s stock worth $6,243,000 after acquiring an additional 74,634 shares during the last quarter. Royal Bank of Canada raised its holdings in shares of BioLife Solutions by 762.8% during the 1st quarter. Royal Bank of Canada now owns 698,251 shares of the medical equipment provider’s stock worth $15,948,000 after acquiring an additional 617,320 shares during the period. Finally, State of Alaska Department of Revenue boosted its position in shares of BioLife Solutions by 10.2% during the 2nd quarter. State of Alaska Department of Revenue now owns 22,096 shares of the medical equipment provider’s stock valued at $475,000 after acquiring an additional 2,048 shares during the last quarter. 93.24% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. Stephens assumed coverage on shares of BioLife Solutions in a research note on Tuesday, July 22nd. They set an “overweight” rating and a $30.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioLife Solutions in a research note on Wednesday, October 8th. Zacks Research upgraded BioLife Solutions from a “hold” rating to a “strong-buy” rating in a research report on Friday, November 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $32.00 price target (up from $30.00) on shares of BioLife Solutions in a research report on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, BioLife Solutions has an average rating of “Moderate Buy” and an average target price of $31.20.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.